ku-0063794

KU-0063794 is a cell-permeable, selective, ATP-competitive small molecule inhibitor of the mammalian target of rapamycin (mTOR), specifically inhibiting both mTOR complex 1 (mTORC1) and complex 2 (mTORC2) with IC50 values around 10 nM. Unlike many other PI3K/mTOR pathway inhibitors, KU-0063794 demonstrates remarkable specificity with negligible activity against 76 other protein kinases and seven lipid kinases, including Class 1 PI3Ks, even at 1000-fold higher concentration. KU-0063794 suppresses mTOR-driven phosphorylation and activation of downstream targets including S6K1, Akt (serine 473), and SGK, but does not affect kinases not regulated by mTOR, such as RSK. Preclinical data show that KU-0063794 induces G1-cell-cycle arrest, suppresses cell growth, and induces autophagy, but not apoptosis, in various cell types. KU-0063794 also exhibits antiproliferative effects in models of keloid disease, non-small cell lung cancer (including EGFR TKI-resistant lines), and renal cell carcinoma xenografts. It has not been approved or developed for human therapeutic or diagnostic use and is primarily used as a research tool for delineating the physiological and pathological roles of mTOR signaling[1][2][3][5].